Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

By Robin L. Carhart-Harris, D. Erritzoe, T. Williams, J. Stone, L. Reed, A. Colasanti, R. Tyacke, Robert Leech, A. Malizia, Kevin Murphy and 5 more. Proceedings of the National Academy of Sciences of the United States of America, 2012

1,086 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Clinical Psychology

View Paper: https://www.semanticscholar.org/paper/db11ee465fd981467763e840fdf21953262f76ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

In Cellular and Molecular Neuroscience

In Clinical Psychology

Citations in the corpus

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. (2016, background): “10 Moreover, data obtained from large-scale population studies have recently challenged the view that psychedelics negatively aﬀ ect mental health, 11–13 with one study’s ﬁ ndings showing lower rates of psychological distress and suicidality among people who had used”
The role of the posterior cingulate cortex in cognition and disease. (2014, background): “The network abnormalities observed in schizophrenia may be directly related to psychotic symptoms (Carhart-Harris et al., 2012a, b, c).”
Psychedelics (2016, methodology): “LFP amplitude in response to sensory stimuliwas decreasedby psilocin administration, concurrently with enhanced CBF.”
Developing Guidelines and Competencies for the Training of Psychedelic Therapists (2017, background): “Carhart-Harris et al. (2017) and Preller et al. (2017) have recently shown breakthrough findings of neural correlates to cognitive fluidity in attributions of relevance and to meaning-making capacity in relation to psilocybin and LSD ingestion, respectively.”
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study (2015, positive): “The past decade has seen a rapid growth of interest in potential clinical applications of the classic hallucinogen psilocybin (Bogenschutz, 2012; Burdick and Adinoff, 2013; Carhart-Harris et al., 2012, 2013; Garcia-Romeu et al., 2013; Grob et al., 2011; Kometer et al., 2012; Nichols, 2014).”
Neural correlates of the LSD experience revealed by multimodal neuroimaging (2016, methodology): “More broadly, the results reinforce the view that resting state ASL, BOLD FC, and MEG measures can be used to inform on the neural correlates of the psychedelic state (9, 16).”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “The former is significant because depressive symptoms have been associated with increased activity in the medial PFC (Drevets et al., 2008; Farb et al., 2011) and normalization of medial PFC activity has been demonstrated with anti-depressant treatment (Deakin et al., 2008; Holtzheimer and Mayberg, ”
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016, background): “As a 5-HT2A agonist, the psilocybin metabolite psilocin directly and indirectly affects various brain cortical and subcortical areas and alters brain network dynamics (Carhart-Harris et al., 2012, 2014; Vollenweider and Kometer, 2010).”
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression (2017, positive): “Moreover, acute brain imaging has suggested that the brain enters a hyperplastic state under psychedelics that may facilitate learning and change (Carhart-Harris et al., 2012; Carhart-Harris, Kaelen, et al., 2016; Carhart-Harris, Muthukumaraswamy, et al., 2016).”
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction (2014, background): “Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases (2014, methodology): “No neuroimaging studies have been conducted with LSD, whereas neuroimaging studies with the LSD-related substances psilocybin (Carhart-Harris et al., 2012; GouzoulisMayfrank et al., 1999; Vollenweider et al., 1997) and dimethyltryptamine (de Araujo et al.”
Serotonin and brain function: a tale of two receptors (2017, background): “Subjective anxiety is inconsistently and only marginally increased by the 5-HT2AR agonists psilocybin and LSD during their acute intoxication state (Carhart-Harris et al., 2012a, 2015a; Griffiths et al., 2006) (although acute panic can occur (Barrett et al., 2016; Carbonaro et al., 2016)), yet…”
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018, methodology): “The development of subjective (Nour et al., 2016), behavioral and biological measures (Carhart-Harris et al., 2012, 2016b; Lebedev et al., 2015; Tagliazucchi et al., 2016) relevant to these constructs, and more importantly, the processes that underlie them, would represent an important advance not…”
Mapping the self in the brain's default mode network (2016, neutral): “Intriguingly, the ingestion of psychedelic drugs has been reported to reduce connectivity within the DMN (Carhart-Harris et al., 2012) and to reduce PCC-mediated network synchronization, the extent of whichwas reported to be correlatedwith a sense of dissolution of the self (Muthukumaraswamy et…”
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014, background): “, Abramson, L. Y., Alloy, L. B., and Hartlage, S. (1989). Processing of ambiguous and unambiguous feedback by depressed and nondepressed college”
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “…between meditative and psychedelic states that have been detected with brain imaging include the following: relative deactivation of the DMN (Carhart-Harris et al., 2012a; Garrison et al., 2013), reduced anticorrelation between the DMN and networks concerned with processing the extrinsic…”